Atria Investments Inc Sells 27 Shares of argenx SE (NASDAQ:ARGX)

Atria Investments Inc lessened its stake in shares of argenx SE (NASDAQ:ARGX) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,649 shares of the company’s stock after selling 27 shares during the quarter. Atria Investments Inc’s holdings in argenx were worth $1,436,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Profund Advisors LLC boosted its stake in shares of argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after acquiring an additional 28 shares in the last quarter. Wealth Alliance boosted its stake in shares of argenx by 4.8% during the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after acquiring an additional 29 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after acquiring an additional 40 shares in the last quarter. Toronto Dominion Bank boosted its stake in shares of argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock worth $119,000 after acquiring an additional 43 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in argenx by 3.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock valued at $737,000 after purchasing an additional 52 shares during the period. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ARGX shares. Piper Sandler increased their target price on argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Guggenheim increased their target price on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Wells Fargo & Company increased their target price on argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Finally, Oppenheimer increased their target price on argenx from $560.00 to $646.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $619.79.

argenx Trading Down 5.2 %

Shares of ARGX opened at $564.23 on Friday. argenx SE has a 1 year low of $327.73 and a 1 year high of $611.22. The stock has a 50 day simple moving average of $552.89 and a 200-day simple moving average of $481.22. The stock has a market cap of $33.74 billion, a PE ratio of -641.16 and a beta of 0.61.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the prior year, the firm posted ($1.25) EPS. On average, sell-side analysts forecast that argenx SE will post 2.2 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.